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Introduction
Glioblastoma multiforme is the most common brain tumor 
in adults.1,2 Despite aggressive treatment protocols, including 
surgical resection followed by radiochemotherapy, glioblastoma 
patients have a median overall survival expectancy of 14 mo.1 
The high progression and recurrence rate after therapy in focal 
masses result from a subset of tumor cells, so-called tumor-stem 
cells, with a very high tumorigenic activity.3,4 The enhanced 
chemo- and radioresistance of glioblastoma and their tumor-
initiating stem cells might be the main reason why conventional 
therapies are considered a palliative venture with no hope of 
cure.5,6 Therefore improving therapeutic success and outcome 
novel treatment strategies are needed.
Cyclic AMP (cAMP) is a second messenger generated by 
adenylyl cyclases representing an important signal transducer 
in several physiologic and pathologic settings, as it can activate 
kinases and is responsible for actions like ion channel regulation.7 
cAMP-related signaling can control apoptosis induction and cell 
growth.7,8 Recently, it was found that cAMP inhibits doxorubicin 
as well as DNA damage-induced apoptosis.9,10
Agonists triggering opioid receptors can activate inhibi-
tory G
i
-proteins, which, in turn, block adenylyl cyclase activity, 
reducing cAMP.11 D,L-methadone is an μ-opioid receptor ago-
nist inducing apoptosis in leukemia cells in vitro and in vivo.12-14 
In addition, D,L-methadone sensitizes leukemia cells for doxo-
rubicin treatment via downregulation of cAMP triggered by 
opioid receptor activation.13 Apoptosis plays a critical role in the 
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Glioblastoma are the most frequent and malignant human brain tumors, having a very poor prognosis. the enhanced 
radio- and chemoresistance of glioblastoma and the glioblastoma stem cells might be the main reason why conventional 
therapies fail. the second messenger cyclic AMp (cAMp) controls cell proliferation, differentiation, and apoptosis. Down-
regulation of cAMp sensitizes tumor cells for anti-cancer treatment. opioid receptor agonists triggering opioid receptors 
can activate inhibitory Gi proteins, which, in turn, block adenylyl cyclase activity reducing cAMp. In this study, we show 
that downregulation of cAMp by opioid receptor activation improves the effectiveness of anti-cancer drugs in treat-
ment of glioblastoma. the μ-opioid receptor agonist D,L-methadone sensitizes glioblastoma as well as the untreatable 
glioblastoma stem cells for doxorubicin-induced apoptosis and activation of apoptosis pathways by reversing deficient 
caspase activation and deficient downregulation of XIAp and Bcl-xL, playing critical roles in glioblastomas’ resistance. 
Blocking opioid receptors using the opioid receptor antagonist naloxone or increasing intracellular cAMp by 3-isobutyl-
1-methylxanthine (IBMX) strongly reduced opioid receptor agonist-induced sensitization for doxorubicin. In addition, 
the opioid receptor agonist D,L-methadone increased doxorubicin uptake and decreased doxorubicin efflux, whereas 
doxorubicin increased opioid receptor expression in glioblastomas. Furthermore, opioid receptor activation using D,L-
methadone inhibited tumor growth significantly in vivo. our findings suggest that opioid receptor activation triggering 
downregulation of cAMp is a promising strategy to inhibit tumor growth and to improve the effectiveness of anti-cancer 
drugs in treatment of glioblastoma and in killing glioblastoma stem cells.
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regulation of various physiological or pathological conditions and 
has also been implied to mediate therapy-induced cytotoxicity 
following chemotherapy and radiation.15,16 Two principle apop-
tosis signaling pathways have been delineated, the death receptor 
(extrinsic) pathway and the mitochondrial (intrinsic) pathway.17 
Activation of either pathway leads to activation of caspases.18
Resistances to current treatment regimens remain a major 
concern in oncology and may be caused by defects in apoptosis 
program.15 Apoptosis signaling may be disrupted by deregulated 
expression and/or function of anti-apoptotic such as Bcl-x
L
 or 
proapoptotic molecules like Bax. The majority of human can-
cers harbor high levels of inhibitor of apoptosis proteins (IAPs), 
e.g., the well-characterized X-linked IAP (XIAP).15,19 Targeting 
these proteins by inhibition or downregulation are novel 
approaches in glioma therapy.20,21
In this study we demonstrate that downregulation of cAMP 
induced by opioid receptor activation using the μ-opioid recep-
tor agonist D,L-methadone sensitizes chemo- and radioresis-
tant glioblastoma cells for doxorubicin-induced apoptosis and 
reverses deficient activation of apoptosis pathways by doxoru-
bicin. Interestingly, glioblastoma stem cells, which seem to be 
the reason for glioblastomas resistances, were strongly killed by 
activation of opioid receptors using D,L-methadone in addition 
to doxorubicin.
Figure 1. opioid receptor activation using D,L-methadone sensitizes glioblastoma cell lines for doxorubicin treatment. (A) opioid receptor expression 
on glioblastoma cells. the glioblastoma cell lines U118MG and A172 were stained with naloxone fluorescein measuring opioid receptor expression (oR, 
thick black curve) by flow cytometry. Controls (Co , unstained cells) are exhibited as thin black curves. (B) A172 and U118MG glioblastoma cells were 
treated with different concentrations of D,L-methadone (10, 3, 1 μg/mL) alone (−Doxo, white columns), with 0.1 μg/mL doxorubicin (+ Doxo, black 
columns) alone or with different concentrations of D,L-methadone (10, 3, 1 μg/mL) in addition to 0.1 μg/mL doxorubicin (+ Doxo, black columns). After 
120 h and 144 h, the percentages of apoptotic cells were measured by hypodiploid DNA analysis. the percentage of specific apoptosis was calculated as 
follows: 100 x [experimental dead cells (%) − spontaneous dead cells in medium (%)] / [100% −spontaneous dead cells in medium (%)].  Columns, mean 
of triplicates; bars, SD < 10%. Similar results were obtained in 3 independent experiments. (C) A172 and U118MG glioblastoma cells were treated with 
different concentrations of D,L-methadone (10, 3, 1 μg/mL) alone (−Doxo, white columns), with 0.3  μg/mL doxorubicin (+Doxo, black columns) alone or 
with different concentrations of D,L-methadone (10, 3, 1 μg/mL) in addition to 0.3 μg/mL doxorubicin (+ Doxo, black columns). After 120 h, the percent-
ages of apoptotic cells were measured by hypodiploid DNA analysis. the percentage of specific apoptosis was calculated as described in Figure 1B. 
Columns, mean of triplicates; bars, SD < 10%. Similar results were obtained in 3 independent experiments.
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Results
Opioid receptor activation increases doxorubicin-induced 
apoptosis in glioblastoma cells
Glioblastomas are hard to kill with anti-cancer drugs or radia-
tion.22 We recently published that the μ-opioid receptor agonist 
D,L-methadone breaks chemo- and radioresistance in leukemia 
cells expressing opioid receptors and sensitizes leukemia cells 
for doxorubicin treatment.12,13 Doxorubicin is an effective sub-
stance in treatment of malignant gliomas in in vitro studies 
and animal models.22 To enhance penetration of doxorubicin 
and to improve doxorubicin delivery across the blood–brain 
barrier, doxorubicin is used as liposomal encapsulated formula-
tion (Caelyx) in vivo.22,23 Glioblastoma cells (A172, U118MG) 
express opioid receptors (Fig. 1A). Therefore, we analyzed if the 
opioid D,L-methadone can also induce cell death in glioblas-
toma cells. A172 and U118MG glioblastoma cells were treated 
with doxorubicin (0.1 μg/mL), D,L-methadone (10, 3, 1 μg/
mL) alone or in combination (Fig. 1B), or A172 and U118MG 
glioblastoma cells were treated with doxorubicin (0.3 μg/mL) 
or D,L-methadone (10, 3, 1 μg/mL) alone or in combination 
(Fig. 1C). A strong induction of cell death was observed by 
co-treatment of D,L-methadone and doxorubicin in A172 and 
U118MG glioblastoma cells (Fig. 1B and C). This suggests 
that opioid receptor activation using D,L-methadone strongly 
potentiates doxorubicin-induced apoptosis in glioblastoma 
cells.
Opioid receptor activation sensitizes primary human glio-
blastoma cells and glioblastoma stem cells for doxorubicin-
induced cell death
To test the clinical relevance of opioid receptor activation 
and whether glioblastoma are sensitized for doxorubicin-induced 
apoptosis, we extended our studies to primary human glioblas-
toma cells and glioblastoma stem cells. Primary human glio-
blastoma cells expressing opioid receptors (Fig. 2A) were treated 
with D,L-methadone (3, 1 μg/mL) or doxorubicin (0.1 μg/mL) 
alone or in combination (Fig. 2B). Therapeutic concentrations 
of D,L-methadone (3, 1 μg/mL) in addition to doxorubicin kill 
strongly primary human glioblastoma cells after 120 h and 144 h 
(Fig. 2B).
Human glioblastoma stem cells are known for their resis-
tances toward radiation and chemotherapeutic drugs responsible 
Figure 2. opioid receptor activation using D,L-methadone sensitizes primary human glioblastoma cells and glioblastoma stem cells for doxorubicin 
treatment. (A) primary human glioblastoma cells were stained with naloxone fluorescein measuring opioid receptor expression (oR, thick black curve) 
by flow cytometry. Control (Co, unstained cells) is exhibited as thin black curve. (B) primary human glioblastoma cells were treated with different 
concentrations of D,L-methadone (3, 1 μg/mL) alone (−Doxo, white columns) with 0.1 μg/mL doxorubicin (+Doxo, black columns) alone or with D,L-
methadone (3, 1 μg/mL) in addition to 0.1 μg/mL doxorubicin (+Doxo, black columns). After 120 h and 144 h, the percentages of apoptotic cells were 
measured by hypodiploid DNA analysis. the percentage of specific apoptosis was calculated as described in Figure 1B. Columns, mean of triplicates, 
bars, SD < 10%. Similar results were obtained in 3 independent experiments. (C) Glioblastoma stem cells were stained with naloxone fluorescein mea-
suring opioid receptor expression (oR, thick black curve) and analyzed by flow cytometry. Control (Co, unstained cells) is exhibited as thin black curve. 
(D) Glioblastoma stem cells were treated with different concentrations of D,L-methadone (10, 3, 1 μg/mL) alone (−Doxo, white columns), with 0.1 μg/
mL doxorubicin (+ Doxo, black columns) alone or with D,L-methadone (3, 1 μg/mL) in addition to 0.1 μg/mL doxorubicin (+ Doxo, black columns). After 
144 h, the percentages of apoptotic cells were measured by hypodiploid DNA analysis. the percentage of specific apoptosis was calculated as described 
in Figure 1B. Columns, mean of triplicates; bars, SD < 10%. Similar results were obtained in 3 independent experiments
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for failure of conventional therapies.5,24 Glioblastoma stem cells 
expressing opioid receptors (Fig. 2C), were treated with D,L-
methadone (10, 3, 1 μg/mL), doxorubicin (0.1 μg/mL), or in 
combination (Fig. 2D). We found a strong induction of apoptosis 
using the combination therapy of D,L-methadone and doxorubi-
cin after 144 h (Fig. 2D). This demonstrates that opioid receptor 
activation by D,L-methadone sensitizes primary human glio-
blastoma and glioblastoma stem cells for doxorubicin-induced 
apoptosis.
Opioid receptor activation reverses deficient caspase activa-
tion by doxorubicin in glioblastoma cells
Deficient caspase activation was observed in chemo- and 
radioresistant glioblastoma cells treated with anti-cancer 
drugs or radiation.25 To clarify the involvement of caspases 
activation in combination therapy of D,L-methadone and 
doxorubicin-induced apoptosis in chemo- and radioresistant 
glioblastomas, we treated A172 glioblastoma cells with D,L-
methadone (3, 1 μg/ mL) or doxorubicin (0.1 μg/mL) alone 
or in combination. After combination treatment, we observed 
strong caspase activation in glioblastoma cells by activation of 
caspase-3, -9, -2, and -10 and cleavage of Poly-(ADP-ribose)-
polymerase (PARP) (Fig. 3A). To investigate the critical role of 
caspases in opioid receptor activation-induced apoptosis, we pre-
incubated A172 cells with the broad-spectrum inhibitor of cas-
pases zVAD.fmk (Fig. 3B). Incubation with zVAD.fmk almost 
completely inhibited apoptosis in glioblastoma cells induced by 
D,L-methadone in addition to doxorubicin, suggesting that cas-
pases are central for opioid receptor activation-mediated sensiti-
zation of glioblastoma cells for doxorubicin treatment (Fig. 3B). 
This demonstrates that opioid receptor activation using D,L-
methadone reverses deficient activation of caspases by doxoru-
bicin in glioblastoma cells.
Figure 3. opioid receptor activation using D,L-methadone sensitizes glioblastoma cell for doxorubicin-induced activation of caspases. (A) D,L-methadone 
restored deficient caspases activation by doxorubicin in glioblastoma cells. A172 were treated with different concentrations of D,L-methadone 
(3, 1 μg/ mL, -Doxo) alone, with 0.1 μg/mL doxorubicin (+Doxo) alone or with D,L-methadone (3, 1 μg/mL) in addition to 0.1 μg/mL doxorubicin (+Doxo). 
After 144 h, western blot analyses were performed. Downregulation of caspase-10 was detected at ~58 kDa and of caspase-2 at ~48 kDa. the active 
fragment of caspase-9 was detected at ~37 kDa, the active fragment of caspase-3 at ~17 kDa and pARp cleavage at ~85 kDa. equal protein loading was 
controlled by anti-β-actin antibody. (B) Inhibition of caspases activation blocks opioid receptor activation-sensitized glioblastoma cells for doxorubicin-
induced apoptosis. Glioblastoma cells A172 were treated with different concentrations of D,L-methadone (10, 3, 1 μg/mL) in combination with 0.1 μg/
mL doxorubicin (+0.1 μg/mL Doxo) without (−zVAD, black columns) or with addition of 50 μmol/L zVAD.fmk (+zVAD, white columns). After 120 h and 
144 h, the percentages of apoptotic cells were measured by hypodiploid DNA analysis. the percentage of specific apoptosis was calculated as described 
in Figure 1B. (C) opioid receptor activation using D,L-methadone sensitizes glioblastoma cell by downregulation of XIAp and Bcl-xL. Glioblastoma cells 
A172 were treated with different concentrations of D,L-methadone (3, 1 μg/mL, -Doxo) alone, with 0.1 μg/mL doxorubicin (+Doxo) alone, or with D,L-
methadone (3, 1 μg/mL) in addition to 0.1 μg/mL doxorubicin (+Doxo) for 144 h. Western blot analyses for XIAp and Bcl-xL were performed. XIAp was 
detected at ~58 kDa and Bcl-xL at ~30 kDa. equal protein loading was controlled by anti-β-actin antibody.
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Opioid receptor activation reverses deficient downregula-
tion of XIAP and Bcl-x
L
 by doxorubicin in glioblastoma cells
Inhibition of XIAP by XIAP inhibitors or Bcl-x
L
 by using 
Bcl-x
L
-antisense oligonucleotides sensitizes glioblastoma cells for 
chemotherapeutic drugs or radiation.20,21 Therefore, we exam-
ined if opioid receptor activation using D,L-methadone can 
also downregulate XIAP or Bcl-x
L
 in doxorubicin-treated A172 
glioblastoma cells. Strong downregulation of XIAP and Bcl-x
L
 
was found in glioblastoma cells treated with D,L-methadone 
(3, 1 μg/mL) in addition to doxorubicin (0.1 μg/mL) (Fig. 3C), 
indicating that opioid receptor activation using D,L-methadone 
in addition to doxorubicin sensitizes glioblastoma cells via down-
regulation of XIAP and Bcl-x
L
.
Opioid receptor activation reverses deficient activation of 
apoptosis pathways by doxorubicin in chemo- and radioresis-
tant glioblastoma stem cells
Glioblastoma stem cells were reported to possess enhanced 
chemoresistance and radioresistance, resulting in the regulation 
of tumor progression and recurrence.5 We next analyzed, if cas-
pases were activated in glioblastoma stem cell-induced apoptosis 
after co-treatment with D,L-methadone and doxorubicin. We 
treated glioblastoma stem cells with D,L-methadone (3 μg/mL) 
or doxorubicin (0.1 μg/mL) alone or in combination. 144 h after 
treatment with D,L-methadone in addition to doxorubicin, we 
observed a strong caspase activation in glioblastoma-intitiating-
stem cells by activation of caspase-3, -9, -2, and -10 and cleavage 
of Poly-(ADP-ribose)-polymerase (PARP) (Fig. 4A). This dem-
onstrates that opioid receptor activation using D,L-methadone 
reversed deficient caspases activation by doxorubicin in glioblas-
toma stem cells.
To determine the role of XIAP and Bcl-x
L
 in chemoresistance 
of glioblastoma stem cells, we treated glioblastoma stem cells 
with D,L-methadone in addition to doxorubicin. After 144 h, 
we observed a strong downregulation of XIAP and Bcl-x
L
 as well 
a strong upregulation of the pro-apoptotic protein Bcl-x
S
 in glio-
blastoma stem cells treated with D,L-methadone (3 μg/mL) in 
combination with doxorubicin (0.1 μg/mL) (Fig. 4B). This sug-
gests that opioid receptor activation using D,L-methadone sensi-
tizes glioblastoma stem cells for doxorubicin-induced apoptosis 
by downregulation of XIAP, Bcl-x
L
 and upregulation of Bcl-x
S
.
Opioid receptor activation using D,L-methadone enhances 
doxorubicin uptake and inhibits its efflux in glioblastoma cells
Doxorubicin resistance is associated with the overexpression 
of P-glycoprotein (p-gp).26-28 D,L-methadone increases doxoru-
bicin uptake and inhibits doxorubicin efflux in leukemia cells.13 
Therefore, we tested the effect of D,L-methadone in doxoru-
bicin uptake and efflux in glioblastoma cells incubated with 
0.3 μg/ mL doxorubicin alone or in combination with 3 μg/mL 
D,L-methadone using flow cytometry. Four, 8, and 24 h after 
treatment, the amount of doxorubicin was enhanced in cells 
treated with the combination of doxorubicin and D,L-methadone 
(Fig. 5A). These findings suggest that D,L-methadone improves 
doxorubicin-uptake in glioblastoma cells.
To test whether D,L-methadone inhibits doxorubicin-efflux 
out of glioblastoma cells, we incubated the glioblastoma cell line 
A172 for 4 h with 0.3 μg/mL doxorubicin alone. After removing 
doxorubicin from supernatant, fresh medium was added with-
out doxorubicin, and cells were treated with or without D,L-
methadone. Cells treated with D,L-methadone had a delayed 
doxorubicin-efflux after 4, 8, and 24 h (Fig. 5B), suggesting that 
D,L-methadone inhibits doxorubicin efflux.
Doxorubicin increases opioid receptor expression in glio-
blastoma cells
In leukemia cells, doxorubicin increases opioid receptor 
expression.13 We analyzed the effect of doxorubicin on expres-
sion of opioid receptors in glioblastoma cells. Glioblastoma 
cells (A172) were incubated with 0.1 μg/mL doxorubicin or left 
untreated. After treatment, the relative amount of opioid recep-
tors on the cell surface of untreated and doxorubicin-treated 
cells was measured flow cytometrically. Doxorubicin enhanced 
strongly the expression of opioid receptors in glioblastoma cells 
(Fig. 5C), indicating that more D,L-methadone molecules can 
bind to glioblastoma cells co-treated with doxorubicin.
Apoptosis induction and caspase activation depend on opi-
oid receptor activation inducing cAMP downregulation
cAMP-related signaling can control apoptosis induction and 
cell growth.7,8 Opioid receptor activation induces cAMP down-
regulation and plays a critical role in D,L-methadone-sensitized 
leukemia cells for doxorubicin treatment.13 To analyze the role 
of opioid receptor activation in apoptosis induction and caspase 
activation in glioblastoma cells, glioblastoma cells A172 were 
treated with the opioid receptor agonist D,L-methadone, doxoru-
bicin, or with the opioid receptor antagonist naloxone alone or in 
different combinations (Fig. 6A–C). Blocking opioid receptors 
by naloxone strongly reduced apoptosis (Fig. 6A and B) and acti-
vation of caspase-9, caspase-3, and cleavage of PARP (Fig. 6C) 
induced by combination treatment with D,L-methadone and 
doxorubicin. This indicates that opioid receptor activation plays a 
critical role in apoptosis induction and caspase activation. Opioid 
receptor stimulation activates inhibitory G
i
-proteins, which, in 
turn, block adenylyl cyclase activity, reducing cAMP.29 IBMX, 
however, increases cAMP levels due to phosphodiesterase inhi-
bition. To analyze the critical role of cAMP in opioid receptor 
activation-induced apoptosis, A172 cells were treated with D,L-
methadone, doxorubicin, and IBMX, either alone or in differ-
ent combinations (Fig. 6D). Upregulation of cAMP by IBMX 
strongly reduced apoptosis induction by combination treatment 
with D,L-methadone and doxorubicin, indicating that opioid 
receptor activation via cAMP downregulation sensitizes glio-
blastoma cells for doxorubicin-induced apoptosis and caspase 
activation.
Opioid receptor activation using D,L-methadone inhibits 
tumor growth in vivo
We extended our in vitro studies using a nude mouse model 
to test the clinical relevance of the anti-cancer potential of 
the μ-opioid receptor agonist D,L-methadone in vivo. Therefore, 
107 U87MG glioblastoma cells were subcutaneously inocu-
lated per nude mouse. After randomization of 16 mice, D,L-
methadone was daily orally administered in 8 mice starting at 
day 1 until the end of experiment, (Fig. 7). D,L-methadone dos-
age was increased weekly from 60 to 120 to 240 mg/kg/d bid. At 
day 33, 24 h after the last treatment with D,L-methadone, the 
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mice were sacrificed. For analyzing serum concentrations of D,L-
methadone in mice 0.5, 1, and 4 h after last D,L-methadone-
application, serum was taken, and D,L-methadone quantified by 
mass spectrometry. In comparison to vehicle-treated mice of the 
control group, the D,L-methadone-treated mice had a signifi-
cantly reduced tumor size at day days 19 to 33 with an optimum 
T/C value of 49% (Fig. 7). The D,L-methadone treatment was 
well tolerated in the dose used and induced only a minor body 
weight loss of 9%. Serum concentrations were found between 
136 ng/mL and 1608 ng/mL of methadone in the time course of 
0.5 to 4 h after D,L-methadone application. These findings dem-
onstrate that opioid receptor activation using D,L-methadone 
inhibits tumor growth of glioblastomas in vivo.
Discussion
Resistance to current treatment strategies, such as chemother-
apy and radiotherapy is still a major problem in oncology and may 
be caused by defects in apoptosis programs.30-32 Current attempts 
to improve therapeutic success and survival of cancer patients 
will likely depend on the successful development of novel strate-
gies to increase the therapeutic efficacy of conventional thera-
pies and to overcome chemo- and radioresistance in cancer.17,32,33 
Induction of apoptosis is a key cytotoxic mechanism of most anti-
tumor therapies.17,33 This complex pathway of programmed cell 
death is blocked in chemo- and radioresistant tumor cells.30,31,34 
Glioblastoma are hardly treatable with anti-cancer drugs. The 
prognosis of glioma patients remains very poor.1 Glioblastoma 
patients have a median overall survival expectancy of 14 mo on 
the standard treatment of surgical resection followed by radio- 
and chemotherapy.1 One of the major problems for glioblastoma 
treatment is the low efficacy of blood–brain penetration of cyto-
toxic agents.22 Temozolomide, carmustine (BCNU), or lomus-
tine (CCNU) are used in conventional therapies alone and/or 
in combination to γ-radiation.35,36 In vitro and in vivo studies 
showed that doxorubicin is an effective substance in treatment 
of malignant gliomas.22 To enhance penetration of doxorubi-
cin, doxorubicin is used as liposomal encapsulated formulation 
(Caelyx) in vivo.22,23
The second messenger cAMP controls cell proliferation, dif-
ferentiation, and apoptosis.7,8 For various tumor cells, like pan-
creatic or leukemia cells, stimulation with different agents could 
demonstrate that cAMP elevation is associated with impaired cell 
death.37-39 This is due to the synthesis of anti-apoptotic proteins, 
inactivation of pro-apoptotic proteins, and activation of PI3K-
dependent Akt. Activation of cAMP plays also a critical role in 
inhibiting DNA damage- and doxorubicin-induced apoptosis 
via p53 dephosphorylation and, furthermore, by NF-κB acti-
vation.9,10 Opioid receptor agonists, exogenous opioids such as 
mophine, methadone, as well as endogenous opioids like endor-
phins, can activate opioid receptors. Opioid receptor stimulation 
activates inhibitory G
i
-proteins, which, in turn, block adenylyl 
cyclase activity, reducing cAMP.29 The μ-opioid receptor agonist 
D,L-methadone is an attractive opioid analgesic, especially for 
patients with pain unresponsive to other analgesics40 and opioid 
withdrawal treatment.41,42 Opioid receptor activation using the 
μ-opioid receptor agonist D,L-methadone sensitizes leukemia 
cells for anti-cancer treatment and 
breaks chemo- and radioresistance 
in leukemia cells expressing opi-
oid receptors.12,13 Glioblastoma 
cells express opioid receptors on 
their surface. We found that the 
μ-opioid receptor agonist D,L-
methadone sensitizes glioblastoma 
cells for doxorubicin-induced apop-
tosis. For glioblastoma stem cells, 
it was shown that their presence 
correlates with clinical outcome.43 
Human glioblastoma stem cells are 
known for their resistance toward 
radiation and chemotherapeutic 
drugs, which are in charge of fail-
ure of conventional therapies.5,24 
Thus, finding strategies that also 
target the tumorigenic popula-
tion of brain tumor stem cells is 
of importance in glioblastoma 
therapy to enhance progression-free 
survival and patients’ outcome.43 
Glioblastoma stem cells express 
high levels of opioid receptors. 
Treatment of resistant glioblastoma 
stem cells with D,L-methadone in 
Figure  4. opioid receptor activation using D,L-methadone reversed deficient activation of apoptotic 
pathways by doxorubicin in glioblastoma stem cells. (A) Glioblastoma stem cells were treated with D,L-
methadone (3 μg/mL) alone, with 0.1 μg/mL doxorubicin (0.1 μg/mL Doxo) alone or with D,L-methadone 
(3 μg/mL) in addition to doxorubicin (0.1 μg/mL Doxo). After 144 h, western blot analyses for caspase-10, 
-2, -9, -3, and pARp were performed. Downregulation of caspase-10 was detected at ~58 kDa and of cas-
pase-2 at ~48 kDa. the active fragment of caspase-9 was detected at ~37 kDa, the active fragment of cas-
pase-3 at ~19 kDa and ~17 kDa and pARp cleavage at ~85 kDa. equal protein loading was controlled by 
anti-β-actin antibody. (B) Glioblastoma stem cells were treated with D,L-methadone (3 μg/mL) alone, with 
0.1 μg/mL doxorubicin (0.1 μg/mL Doxo) alone or with D,L-methadone (3 μg/mL) in addition to doxorubi-
cin (0.1 μg/ mL Doxo) for 144h. Western blot analyses for XIAp, Bcl-xL, and Bcl-xS were performed. XIAp was 
detected at ~58 kDa, Bcl-xL was detected at ~30 kDa, and Bcl-xS was detected at ~27 kDa. equal protein 
loading was controlled by anti-β-actin antibody.
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addition to doxorubicin strongly induced apoptosis, demonstrat-
ing that the μ-opioid receptor agonist D,L-methadone sensitizes 
glioblastoma stem cells for doxorubicin and overcomes chemore-
sistance of glioblastoma stem cells, suggesting that this combi-
nation treatment may provide a therapeutic advantage to reduce 
brain tumor recurrence. In addition, we found that opioid recep-
tor activation using D,L-methadone inhibited tumor growth 
significantly in a nude mouse model in vivo. Opioid receptor 
antagonists like naloxone bind to opioid receptors with higher 
affinity than agonists but do not activate opioid receptors.13 This 
effectively blocks opioid receptors, preventing the response to 
opioids, opiates, and endorphins. We found that blocking opioid 
receptor signaling with the opioid receptor antagonist naloxone 
inhibited D,L-methadone-sensitized glioblastoma cells for doxo-
rubicin-induced apoptosis, indicating that activation of opioid 
receptor signaling pathway is involved in apoptosis induction as 
well as in sensitization for doxorubicin treatment. In addition, 
upregulation of cAMP by inhibition of cAMP phosphodiester-
ases using IBMX reduced the cytotoxicity of combination treat-
ment using D,L-methadone and doxorubicin in glioblastoma 
cells, indicating that the opioid receptor agonist D,L-methadone 
sensitizes glioblastoma cells for doxorubicin-induced apoptosis 
through triggering opioid receptors via downregulation of cAMP.
Deficient activation of caspases was found in chemo- and 
radioresistant cancer cells after anti-cancer drug treatment.44-46 
The μ-opioid receptor agonist D,L-methadone activated cas-
pases in chemo- and radioresistant leukemia cells.12 In glioblas-
toma cells and in the highly resistant glioblastoma stem cells 
D,L-methadone reversed deficient activation of caspases by 
doxorubicin. In addition, sensitization by D,L-methadone for 
doxorubicin treatment was almost completely inhibited by the 
broad-spectrum inhibitor of caspases zVAD.fmk, suggesting that 
caspases play a central role. Blocking opioid receptor signaling 
with the opioid receptor antagonist naloxone strongly reduced 
D,L-methadone-reversed deficient caspases activation of doxoru-
bicin, suggesting that activation of opioid receptors play a critical 
role in caspase activation in glioblastoma.
Inhibitor of apoptosis proteins (IAPs), which are found at 
high expression levels in many tumors, suppress apoptosis by 
inhibiting caspases.47 Therapeutic modulation of IAPs could tar-
get an important checkpoint in resistance.47,48 Among the IAP 
family of proteins, XIAP displays the strongest anti-apoptotic 
properties. XIAP plays a crucial role in deficient activation of 
caspases-3, -7, and caspase-9.48 In glioblastoma cells as well as in 
gliobliastoma-initiating stem cells a strong expression of XIAP 
was found, suggesting that glioblastoma cells are hard to kill.21,47 
Inactivation of XIAP with XIAP inhibitors sensitizes glioblas-
tomas for anti-cancer drug treatment and γ-irradiation.47 The 
μ-opioid receptor agonist D,L-methadone downregulates XIAP 
in chemo- and radioresistant leukemia cells.12 We demonstrate 
that D,L-methadone in co-treatment with doxorubicin strongly 
downregulated XIAP in glioblastomas and glioblastoma stem 
cells. Blocking opioid receptor signaling with the opioid receptor 
antagonist naloxone strongly reduced downregulation of XIAP, 
suggesting that activation of opioid receptor signaling pathway 
using D,L-methadone could sensitize glioblastoma cells and the 
highly resistant glioblastoma stem cells for doxorubicin treatment 
by downregulation of XIAP.
Apoptotic signaling can be blocked by an increase in anti-
apoptotic molecules and/or by a decrease or defective function 
of pro-apoptotic proteins.30 The Bcl-2 family of proteins consists 
of both anti-apoptotic proteins, for example Bcl-2 and Bcl-x
L
, as 
well as pro-apoptotic molecules, like Bcl-x
S
, Bax.49 Bcl-x
L
 is highly 
expressed in glioblastoma cells and involved in tumor angiogenesis 
Figure  5. D,L-methadone enhances doxorubicin uptake and inhibits its efflux whereas doxorubicin enhances opioid receptor expression. (A) D,L-
Methadone enhances doxorubicin-uptake in glioblastoma cells A172. A172 were incubated with 0.3 μg/mL doxorubicin alone (Doxo, white columns) 
or in combination with 3 μg/mL D,L-methadone (Doxo + D,L-Methadon, black columns). After 4, 8, and 24 h incubation, the fluorescence intensity of 
doxorubicin was determined using flow cytometry analysis. the graphic depicts the relative doxorubicin uptake. Columns, mean of triplicates; bars, 
SD < 10%. Similar results were obtained in 3 independent experiments. (B) D,L-methadone inhibits doxorubicin-efflux out of glioblastoma cells A172. 
A172 were incubated with 0.3 μg/mL doxorubicin for 4 h. After washing doxorubicin-treated A172 cells, A172 cells were either left untreated (−D,L-
methadone) or treated with 3 μg/mL D,L-methadone (+D,L-Methadone) and incubated for different points in time (4 h, 8 h, 24 h). Doxorubicin efflux 
was analyzed via doxorubicin fluorescence in cells using flow cytometry. Columns, mean of triplicates; bars, SD < 10%. Similar results were obtained in 
3 independent experiments. (C) Doxorubicin enhances opioid receptor expression. the glioblastama cell line A172 was treated for 120 h with 0.1 μg/mL 
doxorubicin. After staining of doxorubicin-treated (+Doxo) and untreated cells (−Doxo) with naloxone-fluoresceine. Relative fluorescence intensities 
were determined flow cytometrically. X-fold increase in opioid receptor expression is shown after subtracting the cells autofluorescence (−Doxo) and 
doxorubicin fluorescence (+Doxo).
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and resistance to chemotherapy.50 Glioblastoma demonstrating a 
recurrent or progressive disease have an upregulation of Bcl-x
L
. 
Inhibition of Bcl-x
L
 overexpression by antisense oligonucleotides 
leads to a decrease of viability and an increase of chemosensitivity 
in glioblastoma cells.20 We found that therapeutic concentrations 
of the μ-opioid receptor agonist D,L-methadone in addition to 
therapeutic concentrations of doxorubicin strongly downregu-
late Bcl-x
L
. Blocking opioid receptor signaling with the opioid 
receptor antagonist naloxone strongly reduced downregulation of 
Bcl-x
L
, demonstrating that activation of opioid receptor signaling 
pathway using D,L-methadone could sensitize glioblastoma cells 
and glioblastoma stem cells for doxorubicin treatment by down-
regulation of Bcl-x
L
.
Overexpression of p-glycoproteins (p-gp), e.g., MDR-1, is 
involved in the resistance toward chemotherapeutic drugs such as 
doxorubicin and correlates with an enhanced rate of drug efflux.27 
In glioblastoma cells p-gp is overexpressed. Next to doxorubi-
cin, D,L-methadone is a substrate of p-gp.28 D,L-methadone 
increases doxorubicin influx and decreases doxorubicin efflux in 
leukemia cells.13 We found that D,L-methadone treatment 
led to an increase of doxorubicin also in glioblastoma cells by 
enforcing its uptake and inhibiting its efflux, suggesting that 
increased doxorubicin content in glioblastoma cells induced by 
D,L-methadone may be involved in overcoming chemo- and 
radioresistance. Doxorubicin stimulates expression of opioid 
receptors in leukemia cells.13 We found that, doxorubicin also 
enhances stongly expression of opioid receptors in glioblastoma 
cells, indicating that higher amounts of D,L-methadone can bind 
to glioblastoma cells that are co-treated with doxorubicin. These 
results indicate that the enhanced toxicity in combination treat-
ment with D,L-methadone and doxorubicin is associated with 
the upregulation of opioid receptor expression mediated by doxo-
rubicin and furthermore with an increased uptake and decreased 
efflux of doxorubicin mediated by D,L-methadone.
Taken together, activation of opioid receptor pathways using 
the μ-opioid receptor agonist D,L-methadone sensitizes chemo- 
and radioresistant glioblastoma cells and glioblastoma stem 
cells, which are in charge of failure of conventional therapies 
Figure  6. opioid receptor activation triggering downregulation of cAMp plays a critical role in sensitizing glioblastoma cells for doxorubicin treat-
ment. (A and B) Blocking opioid receptor activation inhibits apoptosis induction. Glioblastoma cell line A172 was incubated with 100 μg/mL naloxone 
(Naloxone), 3 μg/mL D,L-methadone (D,L-Methadone) and 0.1 μg/mL doxorubicin (Doxo) alone or in different combinations as indicated. After (A) 
120 h and (B) 144 h, the percentages of apoptotic cells were measured by hypodiploid DNA analysis. (C) Inhibition of opioid receptor activation inhibits 
caspase activation. A172 cells were incubated with 100 μg/mL naloxone (Naloxone), 3 μg/mL D,L-methadone (D,L-Methadone), and 0.1 μg/mL doxo-
rubicin (Doxo) alone or in different combinations as indicated. Western blot analyses for caspase-9, caspase-3, and pARp were performed after 120 h of 
incubation. the active fragment of caspase-9 was detected at ~37 kDa, of caspase-3 at ~17 kDa, and pARp cleavage at ~85 kDa. equal protein loading 
was controlled by anti-β-actin antibody. (D) Increasing cAMp levels via repression of phosphodiesterase activity inhibits apoptosis. A172 cells were incu-
bated for 120 h with 25 μM 3-Isobutyl-1-methylxanthine (IBMX), 3 μg/mL D,L-methadone (D,L-Methadone), and 0.1 μg/mL doxorubicin (Doxo) alone or 
in different combinations as indicated. After 120 h, the percentages of apoptotic cells were measured by hypodiploid DNA analysis. the percentages of 
specific apoptosis was calculated as described in Figure 1B.
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for doxorubicin treatment. In addition, activation of opioid 
receptors inducing downregulation of cAMP reversed deficient 
caspase activation and downregulation of XIAP and Bcl-x
L
 by 
doxorubicin. Futhermore, opioid receptor activation using D,L-
methadone inhibited tumor growth significantly in vivo. Our 
findings provide the foundation for new strategies establishing 
opioid receptor agonists such as D,L-methadone triggering opi-
oid receptor activation as an additional therapeutic anti-cancer 
drug to improve therapeutic success and outcome.
Materials and Methods
Drugs and reagents
D,L-methadone hydrochloride (Methadone, Sigma), doxorubi-
cin (Sigma), and naloxone (Fagron GmbH&Co) were freshly dis-
solved in sterile distilled water prior to each experiment to ensure 
constant quality of the preparations. 3-Isobutyl-1-methylxanthine 
(IBMX, Sigma) was freshly dissolved in 0.01N NaOH.
For in vivo application, we used D,L-methadone (Methaddict, 
Hexal) as 5 mg tablets purchased from the local pharmacy. The 
tablets were pulverized and solubilized freshly before use in 10% 
Tween 80 in saline.
Cell culture
Glioblastoma cell lines A172 and U118MG were obtained 
from the American Type Culture Collection and cultured in 
DMEM supplemented with 1 mmol/L glutamine, 1% penicil-
lin/streptomycin (all of them Invitrogen), 25 mmol/L HEPES 
(Biochrom AG), and with 10% FCS (Lonza) at 37 °C, 95% 
air/5% CO
2
. For experiments, cells were seeded at 7000 cells/
cm2 and allowed to settle for 24 h. From human specimen iso-
lated primary cultured glioblastoma cells51,52 and glioblastoma 
stem cells52,53 were isolated, cultured, and characterized as 
described.51-53 The study was approved by the Ethics Committee, 
Medical Faculty, University of Ulm.
Serum concentrations of methadone
Determination of methadone in serum samples was per-
formed after liquid/liquid extraction using a mass spectrom-
eter equipped with a gas chromatograph (GC/MS). As internal 
standard, d
9
-methadone was added. The mass selective detector 
was operated in electron impact mode. Data were acquired in 
the selected-ion monitoring mode. The analytes were identi-
fied with the following masses m/z 294, 223, 72 (target ion) for 
methadone and m/z 303, 226, and 78 for d
9
-methadone with a 
limit of detection of 0.8 ng/ml and a limit of quantification of 
1.2 ng/mL.
Induction of apoptosis
Glioblastoma cells (7000 cells/cm2) were treated with 10, 3, 
1 μg/mL D,L-methadone (≤3 μg/mL therapeutic plasma con-
centration) alone or in addition doxorubicin in 75 cm2 flasks. 
Further experiments were performed simultaneously after addi-
tion of 100 μg/mL naloxone, 25 μM IBMX. Quantification of 
apoptosis was measured by flow cytometry as described.54 In 
brief, to determine apoptosis, cells were lysed with Nicoletti buf-
fer containing 0.1% sodium citrate plus 0.1% Triton X-100 and 
propidium iodide 50 μg/mL as described by Nicoletti et al.54 
Propidium iodide (PI) stained nuclei were analyzed by flow 
cytometry (FACSCalibur).
Inhibition of D,L-methadone in combination with doxoru-
bicin induced-caspases activation by zVAD.fmk
The broad spectrum tripeptide inhibitor of caspases zVAD.
fmk (benzoylcarbonyl-Val-Ala-Asp-fluoromethyl ketone, 
Enzyme Systems Products) was used in a concentration of 50 
μmol/L. Glioblastoma cells were preincubated with zVAD.fmk 
1 h before D,L-methadone and doxorubicin treatment. After 120 
h and 144 h the percentage of apoptotic cells was measured as 
described above.54
Western blot analysis
Western blot analyses were done as described.55,56 
Immunodetection of PARP, caspase-3, caspase-9, cas-
pase-2, caspase-10, XIAP, Bcl-x
L
, and β-actin was done using 
rabbit-anti-PARP polyclonal antibody (1:5000, Roche), 
mouse-anti-caspase-10 (1:1000, MoBiTec), mouse-anti-cas-
pase-2 (1:1000), mouse-anti-XIAP monoclonal antibody 
(1:1000, BD Transduction Laboratories), rabbit-anti-caspase-3 
monoclonal antibody (1:1000), rabbit-anti-caspase-9 (1:1000, 
Cell Signaling), rabbit-anti-active-caspase-3 polyclonal anti-
body (1:200, Millipore Bioscience Research Reagents), rab-
bit-anti-Bcl-X
S/L
 polyclonal antibody (1:1000, Santa Cruz), and 
mouse-anti-β-actin monoclonal antibody (1:5000, Sigma). 
Peroxidase-conjugated goat-anti-mouse IgG or peroxidase-con-
jugated goat-anti-rabbit IgG (1:5000, Santa Cruz) as secondary 
antibody were used for the enhanced chemoluminescence system 
(ECL, Amersham Pharmacia). Equal protein loading was con-
trolled by β-actin detection.
Analysis of doxorubicin uptake and efflux
For analysis of doxorubicin uptake, the glioblastoma cell 
line A172 was seeded in a density of 7000 cells/cm2 in 12-well 
plates and was either left untreated or incubated with 0.3 μg/mL 
Figure  7. opioid receptor activation using D,L-methadone inhibits 
tumor growth of glioblastoma. the glioblastoma cell linie U87MG (U87) 
was transplanted into nude-mice. Mice were daily treated with D,L-
methadone (n = 8, black quadrate) or vehicle 10%tween 80 in saline 
(n = 8, black diamond). After transplantation mice were observed for 33 d. 
At distinct points in time (as indicated), tumor growth and tumor volume 
were measured. *Significant to control (P < 0.05, Mann–Whitney U test).
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doxorubicin or a combination of 0.3 μg/mL doxorubicin and 3 
μg/mL D,L-methadone. After 4, 8, and 24 h, cells were washed 
and harvested with cell scrapers without trypsinizing. Afterwards 
the relative doxorubicin uptake in cells was analyzed using flow 
cytometry as described.57,58 After 4, 8, and 24 h treatment, apop-
tosis induction could not be observed in glioblastoma cells.
For analysis of doxorubicin efflux, cells were incubated with 
0.3 μg/mL doxorubicin alone for 4 h. After 4 h doxorubicin treat-
ment, cells were washed to remove doxorubicin from medium. 
Next, cells were incubated with fresh medium without doxo-
rubicin or fresh medium containing 3 μg/mL D,L-methadone 
at 37 °C/5%CO
2
 without doxorubicin to measure doxorubicin 
efflux. After different time points, cells were harvested, washed, 
and relative doxorubicin content in glioblastoma cells was ana-
lyzed using flow cytometry as described.57,58
Flow cytometric assay for determination of cell surface opi-
oid receptors
Cells were washed in PBS supplemented with 1% FCS, cen-
trifuged, and resuspended in PBS/1% FCS containing naloxone-
fluoresceine (0.05 mM, Invitrogen). After 30 min of incubation 
at RT, the cells were washed, centrifuged, and resuspended in 
ice-cold PBS/1% FCS. Flow cytometry analysis was performed 
using FACSCalibur (BD).
Nude mice studies
For in vivo use the glioblastoma cell line U87MG (U87)59 was 
chosen. 107 U87 cells were transplanted at day 0 subcutaneously 
into 16 female nude-mice. After randomization oral treatment (by 
gavage) with D,L-methadone was initiated at day 1 and performed 
daily until the end of the experiment with increasing doses: first 
week 60 mg/kg/d, second week 120 mg/kg/d, third week 2 × 120 
mg/kg/d. Tumor size was measured twice weekly at 2 dimensions, 
and tumor volumes were calculated according to the formula 
(length × width2)/2. Mean tumor volumes and standard devia-
tions were calculated per group. Treated to control values (T/C) in 
percent were calculated by relating mean tumor volumes of each 
group at each measurement day to the controls. Individual body 
weight was measured twice per week as parameter for tolerabil-
ity and body weight changes in percent were calculated by relat-
ing the mean values of each group to the first measurement day. 
Serum from D,L-methadone treated mice was taken 0.5, 1, 4, and 
24 h after last D,L-methadone treatment at day 33, respectively. 
D,L-methadone was quantified by mass spectrometry. The serum 
concentrations of methadone were found between 136 ng/mL 
and 1608 ng/mL in the time course of 0.5 h until 4 h after D,L-
methadone application. Mice were sacrificed at day 33 for ethi-
cal reasons. All animal experiments were approved by the local 
responsible authorities (LaGeSo) and performed according to the 
guidelines for animal welfare in oncological experiments.60
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